Julia Ljubimova is Professor of Neurosurgery and Biomedical Sciences, Director of Nanomedicine Research Center at the Department of Neurosurgery at CedarsSinai Medical Center, and Director of Translational Cancer Program, Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center. She has been working in clinical and basic cancer research for her entire career. The major interest is the differential cancer gene expression as a tool for finding novel/ early markers of cancer development, and for working out new nanomedicine drugs against these tumor targets for treatment and/or imaging. One of the novel markers, the structural tumor vessel wall protein laminin-411, is currently in a clinical trial as a prognostic and diagnostic marker for human glial tumor progression. These discoveries led to the development of new technologies for drug delivery and engineering of a new class of anti-cancer nanomedicine drugs and imaging agents. She pioneered new nano immuno drug development to treat brain and breast cancers. Currently, her research is supported by three NIH/NCI, private and industry grants. She is the author of over 70 peer-reviewed publications, reviews and book chapters as well as an inventor on 12 patents and patent applications. Julia Ljubimova is Professor of Neurosurgery and Biomedical Sciences, Director of Nanomedicine Research Center at the Department of Neurosurgery at CedarsSinai Medical Center, and Director of Translational Cancer Program, Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center. She has been working in clinical and basic cancer research for her entire career. The major interest is the differential cancer gene expression as a tool for finding novel/ early markers of cancer development, and for working out new nanomedicine drugs against these tumor targets for treatment and/or imaging. One of the novel markers, the structural tumor vessel wall protein laminin-411, is currently in a clinical trial as a prognostic and diagnostic marker for human glial tumor progression. These discoveries led to the development of new technologies for drug delivery and engineering of a new class of anti-cancer nanomedicine drugs and imaging agents. She pioneered new nano immuno drug development to treat brain and breast cancers. Currently, her research is supported by three NIH/NCI, private and industry grants. She is the author of over 70 peer-reviewed publications, reviews and book chapters as well as an inventor on 12 patents and patent applications.

diagnostics and therapeutics of angiogenesis-related disorders